OBJECTIVE: Recent studies of ovarian cancer have suggested a role for inflammation in carcinogenesis. Data from a population-based case-control study in Hawaii were examined to assess the relation between polymorphisms in cytokines involved with the inflammatory response, specifically members of the interleukin (IL) family and the incidence of ovarian cancer. PATIENTS AND METHODS: The analysis of 182 epithelial ovarian cancer cases and 219 controls focused on the polymorphisms in the following genes: IL-1alpha, IL-1beta, IL-6, IL-10, and IL-18. Genotype data were obtained from blood samples collected in participants' homes, and reproductive, demographic, and lifestyle histories were collected during interview. RESULTS: There were no significant odds ratios (ORs) for ovarian cancer by allelic variants in any of the IL genes after adjusting for age, ethnicity, education, oral contraceptive pill use, pregnancy, and history of tubal ligation. Although there was a significantly reduced risk of ovarian cancer risk among women with an IL-1alpha (-4845) T allele compared to women with two G alleles (OR: 0.59; 95% confidence interval: 0.37-0.97) after adjustment for age and ethnicity, the trend was not significant (p = 0.10). Further examination of the data suggested that women with at least one IL-18 variant allele (a G to C transition at position -137) were at significantly decreased risk of advanced ovarian cancer (OR: 0.51; 95% confidence interval: 0.28-0.90) compared to women with the IL-18 GG genotype. There was a significant difference in the risk of ovarian cancer associated with the IL-18 C allele by stage at diagnosis (p = 0.04 for homogeneity in the ORs): cases with IL-18 GC or CC genotypes were less likely to be diagnosed at regional/distant stages. Analysis of the data within ethnic subgroups revealed a significant positive association of the heterozygous IL-18 GC genotype with ovarian cancer risk among Native Hawaiian women (OR: 9.96; 95% CI: 1.88-52.90). The OR for ovarian cancer was not significant for Native Hawaiian women homozygous for the IL-18 C allele, but only one case and control had the IL-18 CC genotype. CONCLUSIONS: Overall, this study does not support an association of selected IL-1alpha, IL-1beta, IL-6, IL-10, or IL-18 polymorphisms with the risk for ovarian cancer. However, the IL-18 G137C variant may be a marker for ovarian cancer progression or metastasis.
OBJECTIVE: Recent studies of ovarian cancer have suggested a role for inflammation in carcinogenesis. Data from a population-based case-control study in Hawaii were examined to assess the relation between polymorphisms in cytokines involved with the inflammatory response, specifically members of the interleukin (IL) family and the incidence of ovarian cancer. PATIENTS AND METHODS: The analysis of 182 epithelial ovarian cancer cases and 219 controls focused on the polymorphisms in the following genes: IL-1alpha, IL-1beta, IL-6, IL-10, and IL-18. Genotype data were obtained from blood samples collected in participants' homes, and reproductive, demographic, and lifestyle histories were collected during interview. RESULTS: There were no significant odds ratios (ORs) for ovarian cancer by allelic variants in any of the IL genes after adjusting for age, ethnicity, education, oral contraceptive pill use, pregnancy, and history of tubal ligation. Although there was a significantly reduced risk of ovarian cancer risk among women with an IL-1alpha (-4845) T allele compared to women with two G alleles (OR: 0.59; 95% confidence interval: 0.37-0.97) after adjustment for age and ethnicity, the trend was not significant (p = 0.10). Further examination of the data suggested that women with at least one IL-18 variant allele (a G to C transition at position -137) were at significantly decreased risk of advanced ovarian cancer (OR: 0.51; 95% confidence interval: 0.28-0.90) compared to women with the IL-18 GG genotype. There was a significant difference in the risk of ovarian cancer associated with the IL-18 C allele by stage at diagnosis (p = 0.04 for homogeneity in the ORs): cases with IL-18 GC or CC genotypes were less likely to be diagnosed at regional/distant stages. Analysis of the data within ethnic subgroups revealed a significant positive association of the heterozygous IL-18 GC genotype with ovarian cancer risk among Native Hawaiian women (OR: 9.96; 95% CI: 1.88-52.90). The OR for ovarian cancer was not significant for Native Hawaiian women homozygous for the IL-18 C allele, but only one case and control had the IL-18 CC genotype. CONCLUSIONS: Overall, this study does not support an association of selected IL-1alpha, IL-1beta, IL-6, IL-10, or IL-18 polymorphisms with the risk for ovarian cancer. However, the IL-18G137C variant may be a marker for ovarian cancer progression or metastasis.
Authors: Joellen M Schildkraut; Ellen L Goode; Merlise A Clyde; Edwin S Iversen; Patricia G Moorman; Andrew Berchuck; Jeffrey R Marks; Jolanta Lissowska; Louise Brinton; Beata Peplonska; Julie M Cunningham; Robert A Vierkant; David N Rider; Georgia Chenevix-Trench; Penelope M Webb; Jonathan Beesley; Xiaoqing Chen; Catherine Phelan; Rebecca Sutphen; Thomas A Sellers; Leigh Pearce; Anna H Wu; David Van Den Berg; David Conti; Christopher K Elund; Rebecca Anderson; Marc T Goodman; Galina Lurie; Michael E Carney; Pamela J Thompson; Simon A Gayther; Susan J Ramus; Ian Jacobs; Susanne Krüger Kjaer; Estrid Hogdall; Jan Blaakaer; Claus Hogdall; Douglas F Easton; Honglin Song; Paul D P Pharoah; Alice S Whittemore; Valerie McGuire; Lydia Quaye; Hoda Anton-Culver; Argyrios Ziogas; Kathryn L Terry; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger; Brian Calingaert; Stephen Chanock; Mark Sherman; Montserrat Garcia-Closas Journal: Cancer Res Date: 2009-03-10 Impact factor: 12.701
Authors: Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Michael E Carney; Rachel T Palmieri; Paul D P Pharoah; Honglin Song; Estrid Hogdall; Susanne Kruger Kjaer; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Marc T Goodman Journal: Int J Cancer Date: 2011-02-15 Impact factor: 7.396
Authors: Teresa Warchoł; Margarita Lianeri; Mariusz Wudarski; Jan K Lacki; Paweł Piotr Jagodziński Journal: Rheumatol Int Date: 2009-12 Impact factor: 2.631
Authors: Rachel T Palmieri; Melanie A Wilson; Edwin S Iversen; Merlise A Clyde; Brian Calingaert; Patricia G Moorman; Charles Poole; A Rebecca Anderson; Stephanie Anderson; Hoda Anton-Culver; Jonathan Beesley; Estrid Hogdall; Wendy Brewster; Michael E Carney; Xiaoqing Chen; Georgia Chenevix-Trench; Jenny Chang-Claude; Julie M Cunningham; Richard A Dicioccio; Jennifer A Doherty; Douglas F Easton; Christopher K Edlund; Simon A Gayther; Aleksandra Gentry-Maharaj; Ellen L Goode; Marc T Goodman; Susanne Kruger Kjaer; Claus K Hogdall; Michael P Hopkins; Eric L Jenison; Jan Blaakaer; Galina Lurie; Valerie McGuire; Usha Menon; Kirsten B Moysich; Roberta B Ness; Celeste Leigh Pearce; Paul D P Pharoah; Malcolm C Pike; Susan J Ramus; Mary Anne Rossing; Honglin Song; Keith Y Terada; David Vandenberg; Robert A Vierkant; Shan Wang-Gohrke; Penelope M Webb; Alice S Whittemore; Anna H Wu; Argyrios Ziogas; Andrew Berchuck; Joellen M Schildkraut Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-12 Impact factor: 4.254